N@N

Cornerstone Therapeutics Announces Upcoming Investor Events

^{Published on 2011-04-18 05:35:46 - Market Wire}
 

CARY, NC--(Marketwire - April 18, 2011) - Cornerstone Therapeutics Inc. (NASDAQ: [ CRTX ]) today announced updates regarding key upcoming investor relations events.

On Tuesday, May 3, 2011 at 2:10 p.m. EDT, Craig A. Collard, President and Chief Executive Officer, will present a corporate overview at the Deutsche Bank 36th Annual Health Care Conference at the InterContinental Hotel in Boston, MA. A live and archived audio webcast of Cornerstone's presentation will be available through the Investor Relations section of the Company's website, [ www.crtx.com ].

On Thursday, May 12, 2011 at 8:30 a.m. EDT, Cornerstone will host a conference call to discuss its financial results for the quarter ended March 31, 2011. Financial results will be released before the open of the U.S. financial markets the day of the call. Detailed dial-in and webcast information will be provided in advance of the call.

On Wednesday, June 22, 2011 at 10:00 a.m. EDT, Cornerstone will host a conference call to update investors on the strategic direction of the Company. Detailed dial-in and webcast information will be provided in advance of the call.

About Cornerstone Therapeutics
Cornerstone Therapeutics Inc. (NASDAQ: [ CRTX ]), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the respiratory and related markets. Key elements of the Company's strategy are to leverage commercial capabilities by promoting respiratory and related products to high prescribing physicians through its respiratory sales force and to hospital-based healthcare professionals through its hospital sales force; acquire rights to existing patent- or trade secret-protected, branded products, which can be promoted through the same channels to generate on-going high-value earnings streams; advance its development projects and further build a robust pipeline; and generate revenues by marketing approved generic products through its wholly owned subsidiary, Aristos Pharmaceuticals, Inc.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements, our ability to enter into strategic licensing, product acquisition, collaboration or co-promotion transactions on favorable terms, if at all, and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 3, 2011 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.